Early data from the TRIUMPH trials is undeniably compelling, showing unprecedented weight loss of up to 28.7% at 68 weeks significantly outpacing tirzepatide in early comparisons (see our Retatrutide vs Tirzepatide comparison guide)
Thanks for sharing your pincode
Self-pay pricing is also available, with options starting affordably for both initial and follow-up consultations
During the TRIUMPH-1 Phase 3 trial, participants taking the highest dose experienced an average weight loss of 28.3% over 80 weeks
GLP-1 has numerous physiological effects that are desirable in the management of type 2 diabetes and obesity, including regulation of insulin secretion, slowing gastric emptying, suppressing appetite and regulating carbohydrate metabolism
In medial collateral ligament (MCL) injury models, BPC-157 administered intraperitoneally (10 g or 10 ng/kg once daily), topically as a cream layer, or orally in drinking water consistently produced functional, biomechanical, macroscopic, and histological healing improvements throughout the 90-day study period
